Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase 1/2 4Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1Breast 1

Conditions

Neoplasms 3Ovarian Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor, Unspecified, Adult 1Solid Tumor 1Prostatic Neoplasms 1Metastatic Castration Resistant Prostate Cancer 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

Paclitaxel 68Carboplatin 64pembrolizumab 32Cyclophosphamide 32Bevacizumab 27liposomal doxorubicin 24Cisplatin 24Topotecan 21Gemcitabine 21olaparib 18fludarabine 17Taxes 16Docetaxel 15Nivolumab 14Doxorubicin 14niraparib 13veliparib 12Albumin-Bound Paclitaxel 11aldesleukin 9Filgrastim 9fludarabine phosphate 8durvalumab 8Oxaliplatin 8Fluorouracil 8Drug Therapy 8sargramostim 7Peripheral Blood Stem Cell Transplantation 7Magnetic Resonance Spectroscopy 7Leucovorin 7talazoparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Ovarian Neoplasms × rucaparib × Clear all
NCT03552471 2025-02-13

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
25 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03840200 2023-10-30

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Hoffmann-La Roche

Phase 1 Completed
51 enrolled 20 charts
BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡